Recent News and Events

In May of 2024, Legacy BioDesign will celebrate its 20th anniversary in business. We have been fortunate enough to serve clients in almost 20 countries, conducting dozens of projects. Five of the drugs studied at Legacy have become marketed products. Even more are now in late-stage clinical trials.

Dr. Josh Stillahn joined Legacy as a Scientist in 2016, after working in the integrated circuit industry. Dr. Stillahn was recently promoted to Principal Scientist as of January 1, 2024. He joins Dr. Ryan Holcomb and Dr. Robert Payne as Principal Scientists at Legacy.

The scholarly impact of Dr. Mark Manning’s work, as reported by ResearchGate, includes over 150 scientific publications that have garnered over 37,000 reads through the year 2023. In addition, his work has received over 10,000 citations.

One of Legacy’s seminal review articles, “Stability of Protein Pharmaceuticals: An Update,” published in 2010, has received over 800 citations and enjoys the distinction of being recognized by Web of Science as a Highly Cited Article, a credit that only 1% of articles achieve.

Furthermore, the article on buffers authored by Legacy scientists (Zbacnik et al., J. Pharm. Sci. 2017, 106: 713-733) was recognized in a review article by Baek and Zydney in Current Opinions in Biotechnology 2018, 53: 59-64, for its outstanding relevance.

Ryan Manning from Great Lakes Bio Design (Charlotte, MI), our partner laboratory, continues to focus on AF4 method development and analysis. More recently, Ryan has expanded his efforts into subvisible particle analysis of biopharmaceuticals. Since January 2014, Great Lakes Bio Design has provided critical analytical support for Legacy, making significant contributions to multiple Legacy projects since its inception.